Subcommittee pauses bill on disclosure of inactive ingredients after industry, patient concerns

Senate Bill 486, introduced by Senator Stewart, would require manufacturers to disclose inactive ingredient sources in supplements and drugs in Virginia, including potential gluten-containing components, subject to the limits of federal law. The Social Services Subcommittee heard testimony and ultimately voted to carry the bill over to 2027 and ask for an agency review.

Senator Stewart framed the bill around a constituent case in which a person with celiac disease discovered gluten in treatment products during cancer care and said even treating physicians were unaware of the ingredient. He said the measure is designed to give patients and clinicians clearer information about ingredient sources so people with severe allergies or autoimmune conditions can make informed decisions.

Scott Johnson, representing the Consumer Health Products Association, told the committee federal labeling rules and testing technology complicate the proposal. "The federal law basically recognizes that our testing capability cannot detect anything below 20 parts per million," Johnson said, adding that labeling and enforcement are governed at the federal level and that some processing additives are not required to appear on labels. He warned the bill as drafted could create a conflict with federal law.

Kathy Bender, who identified herself online as someone with celiac disease and cancer, described difficulties verifying whether prescription and over-the-counter products contained wheat or gluten. "Imagine youre prescribed a life-saving medication, but hidden within its formula is an ingredient that could trigger a severe allergic reaction," she said, urging clearer disclosure of ingredient sources and allergen flags.

Committee members pressed on feasibility and enforcement. Delegates asked whether pharmacists and current labeling rules already address the issue; Johnson and other witnesses noted federal standards and a 20 ppm testing threshold as practical constraints. Members discussed asking VDACS to study implementation and fiscal impacts.

By voice vote the subcommittee approved a motion to carry SB486 over to 2027 and requested Chairman Willett send a letter to VDACS to examine how the policy could be implemented and whether federal requirements create conflicts or budget implications. The motion to carry over passed without recorded opposition.

Next steps: the bill is carried to 2027 for further work with VDACS and stakeholders; no final legislative action was taken today.